Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 6/20 | 0.48 |
| ▸ | HTR1A | P08908 | 5/20 | 0.48 |
| ▸ | DRD2 | P14416 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | HTR6 | P50406 | 4/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194951 | 0.98 | DRD2 (0.46) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL1253364 | 0.94 | HTR1A (0.50) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL3435445 | 0.91 | HTR7 (0.42) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL2195717 | 0.91 | HTR7 (0.46) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL2196552 | 0.90 | HTR7 (0.45) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL1255390 | 0.90 | HTR7 (0.45) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL2194495 | 0.89 | DRD2 (0.45) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL2847043 | 0.88 | SUV39H2 (0.43) | HTR7HTR1AHTR2ASIGMAR1KCNH2 | |
| SCHEMBL2192165 | 0.88 | HTR7 (0.46) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL2197948 | 0.88 | KDM4E (0.50) | HTR7HTR1ADRD2HTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795266-B2 | Tetrahydroindolone derivatives for treament of neurological conditions | ABRAXIS BIOSCIENCE, INC. | 2010-09-14 | — | — | US | claimed |
| EP-2219648-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | Cenomed Biosciences, LLC (US) | 2010-08-25 | — | — | EP | claimed |
| US-20090156609-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERZAINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2009-06-18 | — | — | US | claimed |
| WO-2009062134-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | CENOMED BIOSCIENCES, LLC (US) | 2009-05-14 | — | — | WO | claimed |
| US-20150051219-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | HELTON DAVID REED (US) | 2015-02-19 | — | — | US | disclosed |
| US-8598180-B2 | Tetrahydroindolone derivatives for treatment of neurological conditions | ABRAXIS BIOSCIENCE, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-1715921-B1 | Tetrahydroindolone derivatives for treatment of neurological conditions | ABRAXIS BIOSCIENCE INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20110172242-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2011-07-14 | — | — | US | disclosed |
| EP-2285373-A2 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | Cenomed Biosciences, LLC (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20100305141-A1 | TETRAHYDROINDOLONE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL CONDITIONS | ABRAXIS BIOSCIENCE, INC. | 2010-12-02 | — | — | US | disclosed |
| US-7795266-B2 | Tetrahydroindolone derivatives for treament of neurological conditions | ABRAXIS BIOSCIENCE, INC. | 2010-09-14 | — | — | US | disclosed |
| EP-2219648-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | Cenomed Biosciences, LLC (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090156609-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERZAINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090156609-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERZAINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090156609-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERZAINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2009-06-18 | — | — | US | disclosed |
| WO-2009062134-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | CENOMED BIOSCIENCES, LLC (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009062134-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | CENOMED BIOSCIENCES, LLC (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20070208030-A1 | Tetrahydroindolone Derivatives for Treament of Neurological Conditions | ABRAXIS BIOSCIENCE, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| EP-1715921-A2 | TETRAHYDROINDOLONE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL CONDITIONS | Cenomed, Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005030148-A2 | TETRAHYDROINDOLONE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL CONDITIONS | CENOMED, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208030-A1 | Tetrahydroindolone Derivatives for Treament of Neurological Conditions | TPH2, TPH1, GRIK5 | HTR7 114/4885HTR1A 66/4885DRD2 646/4885 |
| US-20090156609-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERZAINE COMPOUNDS | HTR5A, HTR2C, HTR3B | HTR7 20/4885HTR1A 8/4885DRD2 21/4885 |
| US-20110172242-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | HTR7 199/4885HTR1A 440/4885DRD2 1585/4885 |
| US-20150051219-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | HTR7 199/4885HTR1A 440/4885DRD2 1585/4885 |
| US-20100305141-A1 | TETRAHYDROINDOLONE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL CONDITIONS | NLN, CYP11B2, GRIN2C | HTR7 59/4885HTR1A 86/4885DRD2 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.